<DOC>
	<DOCNO>NCT00550953</DOCNO>
	<brief_summary>The primary purpose study : Demonstrate fixed-dose combination telmisartan 40 mg plus amlodipine 5 mg superior telmisartan 40 mg alone patient essential hypertension inadequately control telmisartan 40 mg monotherapy .</brief_summary>
	<brief_title>Filtered Trial Telmisartan 40mg Non-responder</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>1 . Essential hypertensive patient satisfy nonresponder criterion 2 . Male Female 3 . Age 20 year old 4 . Outpatient 1 . Taking four antihypertensive medication 2 . Secondary hypertension 3 . Mean seat diastolic blood pressure ( DBP ) &gt; 114 mmHg and/or mean seat systolic blood pressure ( SBP ) &gt; 200 mmHg Visit 1 , 2 , 3 , 4 , mean seat DBP &lt; 90 mmHg Visit 3 . 4 . Sustained ventricular tachycardia clinically relevant cardiac arrhythmia 5 . Congestive heart failure patient New York Heart Association ( NYHA ) functional class IIIIV 6 . History myocardial infarction cardiac surgery within last 6 month 7 . History coronary artery bypass graft percutaneous coronary intervention ( PCI ) within last 3 month 8 . History unstable angina within last 3 month 9 . Hypertrophic obstructive cardiomyopathy , aortic stenosis , hemodynamically relevant stenosis aortic mitral valve 10 . History stroke transient ischemic attack within last 6 month 11 . History sudden exacerbation renal function angiotensin II receptor blocker ( ARBs ) angiotensin convert enzyme ( ACE ) inhibitor , patient postrenal transplant postnephrectomy 12 . Experienced characteristic symptom angioedema treatment ARBs ACE inhibitor 13 . Known hypersensitivity component investigational drug , know hypersensitivity dihydropyridine derive drug 14 . Hepatic and/or renal dysfunction 15 . Diagnosed biliary atresia cholestasis 16 . Hyperkalemia 17 . Dehydration 18 . Sodium deficiency 19 . Chronic administration high dos acidic nonsteroidal antiinflammatory drug ( NSAIDs ) 20 . Patients change restrict administration dosage study period 21 . Premenopausal woman meet one follow 1 3 : Pregnant possibly pregnant ( 1 ) Nursing ( 2 ) Desire become pregnant study period ( 3 ) 22 . Drug alcohol dependency 23 . Complication malignant tumour disease require immunosuppressant 24 . Compliance &lt; 80 % &gt; 120 % runin period 25 . Receiving investigational therapy within 3 month 26 . Judged inappropriate investigator subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>